US EditionCorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services
- CorestemChemon has formed a strategic partnership with ATG Lifetech to enhance preclinical services.
- The collaboration aims to provide precision-driven non-clinical solutions for pharmaceutical companies globally.
- CorestemChemon's partnership supports its plan to expand high-margin CRO services, expecting revenue-generating offerings by late 2025.
- Global service launches will target biotech and pharmaceutical customers requiring preclinical testing.
72 Articles
72 Articles
CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services - PressReach
Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery SEOUL, South Korea, July 20, 2025 /PRNewswire/ — CorestemChemon, a leading GLP-certified preclinical CRO based in South Korea, has entered into a strategic partnership with ATG Lifetech, a biotechnology company specializing in transcriptome analytics and organoid-based modeling. This collaboration aims to deliver next-gener…
CorestemChemon Goes Global With ATG Lifetech CRO Alliance
SEOUL, South Korea, July 21, 2025 /PRNewswire/ -- CorestemChemon, a leading GLP-certified preclinical CRO based in South Korea, has entered into a strategic partnership with ATG Lifetech, a biotechnology company specializing in transcriptome analytics and organoid-based modeling. This collaboration aims to deliver next-generation, precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures across the U.S., Europe, an…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
